Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) EBIT: 2009-2024

Historic EBIT for Myriad Genetics (MYGN) over the last 16 years, with Dec 2024 value amounting to -$123.5 million.

  • Myriad Genetics' EBIT fell 16.50% to -$23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$420.5 million, marking a year-over-year decrease of 263.13%. This contributed to the annual value of -$123.5 million for FY2024, which is 52.02% up from last year.
  • Latest data reveals that Myriad Genetics reported EBIT of -$123.5 million as of FY2024, which was up 52.02% from -$257.4 million recorded in FY2023.
  • Myriad Genetics' EBIT's 5-year high stood at -$123.5 million during FY2024, with a 5-year trough of -$289.7 million in FY2020.
  • Over the past 3 years, Myriad Genetics' median EBIT value was -$140.6 million (recorded in 2022), while the average stood at -$173.8 million.
  • Its EBIT has fluctuated over the past 5 years, first plummeted by 3,148.68% in 2020, then skyrocketed by 52.02% in 2024.
  • Over the past 5 years, Myriad Genetics' EBIT (Yearly) stood at -$231.7 million in 2020, then reached -$289.7 million in 2020, then spiked by 34.24% to -$190.5 million in 2021, then increased by 26.19% to -$140.6 million in 2022, then slumped by 83.07% to -$257.4 million in 2023, then skyrocketed by 52.02% to -$123.5 million in 2024.